# Jade Biosciences Inc. (JBIO) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $19.90, market value $1.3 billion.

## Valuation
- **P/E (trailing): n/a** (negative earnings). Jade Biosciences Inc. reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Price / book: 2.9×**. The shares trade at 2.9× book value; book value is a meaningful part of the valuation.

## Profitability
- **Return on equity: -38.3%**. Return on equity is negative because earnings are negative.

## Growth
- **EPS growth (1 yr): 85.5%**. Earnings per share rose 85.5%.

## Financial health
- **Current ratio: 21.09** (quick 21.09). Current assets cover the next year's liabilities 21.09 times.
- **Piotroski F-score: 3/9**. 3 of 9 checks pass: weak or deteriorating financials.

## Dividends
- **Dividend: none**. Jade Biosciences Inc. does not currently pay a dividend.

## Analyst view
- **Analyst consensus: strong_buy** (8 analysts). 8 analysts cover Jade Biosciences Inc.; the consensus is strong_buy, with an average price target of $50.13 (+152% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): 155.8%** (YTD 29.0%, 3-mo 17.5%). The shares are up 155.8% over twelve months including dividends.
- **From 52-week high: -28.9%** (188.0% above the low). Trading 29% below its 52-week high.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 40**. An RSI of 40 is neutral.
- **Beta (1 yr): 1.37** (volatility 74%). Beta of 1.37 against the S&P 500: the shares move much more than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=JBIO · Page: https://foliofundamentals.com/stocks/jbio

Not investment advice.